Shots:

• Exact Sciences to acquire Thrive in all cash & stock transaction for ~2.15B out of which $1.7B would be payable at closing- consisting of 65% in Exact Sciences common stock and 35% in cash along with ~$450M as milestones related to the development and commercialization of a blood-based- multi-cancer screening test. The transaction is expected to be close in Q1’21
• The acquisition will establish Exact Sciences as a leading competitor in blood-based- multi-cancer screening with the addition of Thrive's- CancerSEEK. The agreement will accelerate the approval- availability- and adoption of multi-cancer screening
• Additionally- Exact Sciences also acquires Base Genomics to extend its DNA methylation capabilities. The acquisition will boost Exact Sciences' efforts in cancer diagnostics across the continuum

 ­to­  Ref: Exact Sciences | Image: Canva